301130.SZ
西点药业
SZSE · Healthcare · C 制造业 · CN
CNY 33.09
+5.45%Sep 3, 2026, 07:51 UTC
Xidian Pharmaceutical received a drug supplementary application approval notice from China's National Medical Products Administration for potassium chloride granules, approving the transfer of the marketing authorization holder from Suzhou Langke Biotechnology to Xidian.
Source:Aug 25, 2026, 09:05 UTC
Xidian Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders fell 64.21% year-on-year to 8.9272 million yuan, with revenue down 20.95% to 101 million yuan.
Source:Aug 20, 2026, 07:47 UTC
Xidian Pharmaceutical announced that its registration application for Potassium Chloride Granules was accepted by China's National Medical Products Administration (NMPA).
Source: